LeadIQ logo
Learn more at LeadIQ.com

Insights

Strategic merger Merged BerGenBio with Oncoinvent to form Oncoinvent ASA, signaling a pivot toward radiopharmaceutical cancer therapies and potential cross-sell opportunities between biotech pipeline assets and radiopharma capabilities.

Targeted oncology focus Oncoinvent specializes in alpha radiation therapy for abdominal cavity cancers with limited options, presenting a niche where clinical differentiation and potential companion diagnostics could open discussions with early adopters and specialty centers.

Phase 2 momentum Active recruitment for phase 2 trials in Norway and internationally indicates near-term engagement with clinical sites, CROs, and investigator networks that sales teams can target for research collaborations, site partnerships, and educational outreach.

Executive leadership Recent CFO appointment and CEO appointment history underscore evolving financial strategy and performance management, suggesting opportunities to offer financing solutions, grant support programs, or strategic partnership structures to accelerate trial and commercialization plans.

Strategic partnerships Past and ongoing collaborations, including ARTBIO facilities, plus a merged platform, create openings for co-development deals, manufacturing partnerships, and regional distribution agreements to accelerate deployment of radiopharma products.

Similar companies to BerGenBio ASA - Merged with Oncoinvent ASA

BerGenBio ASA - Merged with Oncoinvent ASA Tech Stack

BerGenBio ASA - Merged with Oncoinvent ASA uses 8 technology products and services including Open Graph, MySQL, Shopify, and more. Explore BerGenBio ASA - Merged with Oncoinvent ASA's tech stack below.

  • Open Graph
    Content Management System
  • MySQL
    Database
  • Shopify
    E-commerce
  • jQuery
    Javascript Libraries
  • reCAPTCHA
    Security
  • MediaElement.js
    Video Players
  • X-Content-Type-Options
    Web & Portal Technology
  • Supsystic
    Web Tools And Plugins

Media & News

BerGenBio ASA - Merged with Oncoinvent ASA's Email Address Formats

BerGenBio ASA - Merged with Oncoinvent ASA uses at least 2 format(s):
BerGenBio ASA - Merged with Oncoinvent ASA Email FormatsExamplePercentage
First.Last@bergenbio.comJohn.Doe@bergenbio.com
95%
Last@bergenbio.comDoe@bergenbio.com
3%
First_Last@bergenbio.comJohn_Doe@bergenbio.com
2%
Last@oncoinvent.comDoe@oncoinvent.com
48%
First.Last@oncoinvent.comJohn.Doe@oncoinvent.com
36%
First.Middle.Last@oncoinvent.comJohn.Michael.Doe@oncoinvent.com
15%
FirstL@oncoinvent.comJohnD@oncoinvent.com
1%

Frequently Asked Questions

What is BerGenBio ASA - Merged with Oncoinvent ASA's phone number?

Minus sign iconPlus sign icon You can contact BerGenBio ASA - Merged with Oncoinvent ASA's main corporate office by phone at
+47-55-54-3****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BerGenBio ASA - Merged with Oncoinvent ASA's official website and social media links?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's official website is oncoinvent.com and has social profiles on LinkedInCrunchbase.

How much revenue does BerGenBio ASA - Merged with Oncoinvent ASA generate?

Minus sign iconPlus sign icon As of July 2026, BerGenBio ASA - Merged with Oncoinvent ASA's annual revenue is estimated to be <$1M.

What is BerGenBio ASA - Merged with Oncoinvent ASA's SIC code NAICS code?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BerGenBio ASA - Merged with Oncoinvent ASA have currently?

Minus sign iconPlus sign iconAs of July 2026, BerGenBio ASA - Merged with Oncoinvent ASA has approximately 6 employees across 1 continents, including Europe. Key team members include Chief People Officer: D. M.Full Time Senior Researcher, Vp Of Contract Services: T. S.Associate Director, Global Regulatory Affairs: K. W.. Explore BerGenBio ASA - Merged with Oncoinvent ASA's employee directory with LeadIQ.

What industry does BerGenBio ASA - Merged with Oncoinvent ASA belong to?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA operates in the Biotechnology Research industry.

What technology does BerGenBio ASA - Merged with Oncoinvent ASA use?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's tech stack includes Open GraphMySQLShopifyjQueryreCAPTCHAMediaElement.jsX-Content-Type-OptionsSupsystic.

What is BerGenBio ASA - Merged with Oncoinvent ASA's email format?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA's email format typically follows the pattern of First.Last@bergenbio.com. Find more BerGenBio ASA - Merged with Oncoinvent ASA email formats with LeadIQ.

How much funding has BerGenBio ASA - Merged with Oncoinvent ASA raised to date?

Minus sign iconPlus sign icon As of July 2026, BerGenBio ASA - Merged with Oncoinvent ASA has raised $183M in funding. The last funding round occurred on Nov 30, 2023 for $23M.

When was BerGenBio ASA - Merged with Oncoinvent ASA founded?

Minus sign iconPlus sign iconBerGenBio ASA - Merged with Oncoinvent ASA was founded in 2008.
BerGenBio ASA - Merged with Oncoinvent ASA logo

BerGenBio ASA - Merged with Oncoinvent ASA

Biotechnology ResearchVestland, Norway2-10 Employees

On 29 October 2025, BerGenBio ASA merged with Oncoinvent ASA, and the combined entity operates under the name Oncoinvent ASA. The company is in the biotechnology research industry and is based in Bergen, Norway (address: 91 Jonas Lies Vei Bergen, Vestland 5009 Norway), with a small workforce of 2 to 10 employees. Oncoinvent ASA is developing Radspherin, a receptor-independent alpha radiation therapy for cancers in the abdominal cavity. The company has begun recruitment for phase 2 studies in Norway and internationally, with preliminary studies reporting positive findings. BerGenBio’s LinkedIn page is being maintained only as a historical archive following the merger.

Section iconCompany Overview

Phone number
+47-55-54-3****
Website
oncoinvent.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
2-10

Section iconMedia & News

Section iconFunding & Financials

  • $183M

    BerGenBio ASA - Merged with Oncoinvent ASA has raised a total of $183M of funding over 10 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $23Mas a post_ipo_debt.

  • <$1M

    BerGenBio ASA - Merged with Oncoinvent ASA's revenue is estimated to be in the range of <$1M

Section iconFunding & Financials

  • $183M

    BerGenBio ASA - Merged with Oncoinvent ASA has raised a total of $183M of funding over 10 rounds. Their latest funding round was raised on Nov 30, 2023 in the amount of $23Mas a post_ipo_debt.

  • <$1M

    BerGenBio ASA - Merged with Oncoinvent ASA's revenue is estimated to be in the range of <$1M

Company Leadership

  • Stylized image of a person
    D. M.
    Chief People Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. S.
    Full Time Senior Researcher, Vp Of Contract Services
    Phone icon
    Mobile Phone
  • Stylized image of a person
    K. W.
    Associate Director, Global Regulatory Affairs
    Phone icon
    Mobile Phone
  • Stylized image of a person
    D. M.
    Director Of Biomarkers And Research
    Phone icon
    Mobile Phone
  • Stylized image of a person
    C. B. D.
    Finance Director
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.